Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab ; volume:19 ; number:1 ; day:21 ; month:10 ; year:2019 ; pages:1-10 ; date:12.2019
BMC cancer ; 19, Heft 1 (21.10.2019), 1-10, 12.2019
- Urheber
-
Masuda, Ken
Shoji, Hirokazu
Nagashima, Kengo
Yamamoto, Shun
Ishikawa, Masashi
Imazeki, Hiroshi
Aoki, Masahiko
Miyamoto, Takahiro
Hirano, Hidekazu
Honma, Yoshitaka
Iwasa, Satoru
Okita, Natsuko
Takashima, Atsuo
Kato, Ken
Boku, Narikazu
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-019-6150-y
- URN
-
urn:nbn:de:101:1-2020021522515025303144
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Masuda, Ken
- Shoji, Hirokazu
- Nagashima, Kengo
- Yamamoto, Shun
- Ishikawa, Masashi
- Imazeki, Hiroshi
- Aoki, Masahiko
- Miyamoto, Takahiro
- Hirano, Hidekazu
- Honma, Yoshitaka
- Iwasa, Satoru
- Okita, Natsuko
- Takashima, Atsuo
- Kato, Ken
- Boku, Narikazu
- SpringerLink (Online service)
Ähnliche Objekte (12)
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
Immune-related prognosis biomarkers associated with osteosarcoma microenvironment
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events
Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report
Editorial: Immune-Related Adverse Events for Patients With Lung Cancer
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab
Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
Immune-related prognosis biomarkers associated with osteosarcoma microenvironment
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events
Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report
Editorial: Immune-Related Adverse Events for Patients With Lung Cancer
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab
Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report
Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
Immune-related prognosis biomarkers associated with osteosarcoma microenvironment
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events
Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report
Editorial: Immune-Related Adverse Events for Patients With Lung Cancer
Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab
Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report
CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab